

10/13/04 11:10 FAX 858 810 1454

LICATA & TYRRELL

+ PTOBF

0005

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 2

RECEIVED  
CENTRAL FAX CENTER

OCT 13 2004

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-12 (canceled)

Claim <sup>1</sup>13 (previously presented): A method of obtaining glial cells comprising:

(a) isolating glial restricted precursor cells from central nervous system tissue by negative immunoselection of E-NCAM positive cells followed by positive immunoselection with an A2B5 antibody, said glial restricted precursor cells being immunonegative for PDGF- $\alpha$  receptor, PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen; and

(b) plating said isolated glial restricted precursor cells of step (a) under differentiating conditions, thereby causing said isolated glial restricted precursor cells to differentiate into glial cells.

<sup>2</sup>Claim <sup>10</sup>14 (currently amended): The method of claim <sup>13</sup>13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of ~~a factor~~ fetal calf serum that promotes differentiation into non-process bearing A2B5-GFAP<sup>+</sup> astrocytes and said glial cells are A2B5-GFAP<sup>+</sup> astrocytes.

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 3

Claim 15: (canceled)

<sup>3</sup>  
Claim ~~16~~ (currently amended): The method of claim <sup>1</sup>~~13~~<sup>9</sup> wherein said differentiating conditions comprise addition to growth medium of an effective amount of ~~a factor~~ ciliary neurotrophic factor and basic fibroblast growth factor that promotes differentiation into process bearing A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes and said glial cells are A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes.

Claim 17: (canceled)

<sup>4</sup>  
Claim ~~18~~ (currently amended): The method of claim <sup>1</sup>~~13~~<sup>9</sup> wherein said differentiating conditions comprise addition to growth medium of an effective amount of ~~a factor~~ platelet-derived growth factor and thyroid hormone (T3) that promotes differentiation into oligodendrocytes and said glial cells are oligodendrocytes.

Claims 19-48 (canceled)

<sup>5</sup>  
Claim ~~49~~ (previously presented): A method for continuously propagating glial restricted precursor cells immunonegative for PDGF- $\alpha$  receptor, PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen comprising the steps of:

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 4

(a) isolating glial restricted precursor cells from central nervous system tissue by negative immunoselection of E-NCAM positive cells followed by positive immunoselection with an A2B5 antibody, said glial restricted precursor cells being immunonegative for PDGF- $\alpha$  receptor, PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen; and

(b) culturing said isolated glial restricted precursor cells of step (a) *in vitro* in the presence of minimal essential salts and effective amounts of platelet derived growth factor and fibroblast growth factor.